EGFR pathway-based gene signatures of druggable gene mutations in melanoma, breast, lung, and thyroid cancers
M Raevskiy, M Sorokin, U Vladimirova… - Biochemistry …, 2021 - Springer
Abstract EGFR, BRAF, PIK3CA, and KRAS genes play major roles in EGFR pathway, and
accommodate activating mutations that predict response to many targeted therapeutics …
accommodate activating mutations that predict response to many targeted therapeutics …
A comparative survey of functional footprints of EGFR pathway mutations in human cancers
Genes functioning in epidermal growth factor receptor (EGFR) signaling pathways are
among the most frequently activated oncogenes in human cancers. We have conducted a …
among the most frequently activated oncogenes in human cancers. We have conducted a …
[HTML][HTML] Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF …
Y Yu, X Wang, Q Li, M Zhang, P Xu… - Oncology …, 2018 - spandidos-publications.com
Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer
have a high frequency (~ 50%) of oncogenic BRAF mutations, particularly BRAF V600E …
have a high frequency (~ 50%) of oncogenic BRAF mutations, particularly BRAF V600E …
[HTML][HTML] Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for …
This review article deals with the analysis and the detection of the morphological features
associated with somatic mutations, mostly BRAF V600E mutation, on both cytological and …
associated with somatic mutations, mostly BRAF V600E mutation, on both cytological and …
[HTML][HTML] Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
Abstract Background The BRAF V600E gene encodes for the mutant BRAF V600E protein,
which triggers downstream oncogenic signaling in thyroid cancer. Since most currently …
which triggers downstream oncogenic signaling in thyroid cancer. Since most currently …
Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
Z Tang, S Jiang, R Du, ET Petri, A El-Telbany… - Oncogene, 2009 - nature.com
Targeted therapy against epidermal growth factor receptor (EGFR) represents a major
therapeutic advance in lung cancer treatment. Somatic mutations of the EGFR gene, most …
therapeutic advance in lung cancer treatment. Somatic mutations of the EGFR gene, most …
[HTML][HTML] Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer
SS Fois, P Paliogiannis, A Zinellu, AG Fois… - International journal of …, 2021 - mdpi.com
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …
has enriched our understanding of cancer initiation and progression and has become …
[HTML][HTML] Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing
E Borràs, I Jurado, I Hernan, MJ Gamundi, M Dias… - BMC cancer, 2011 - Springer
Background Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and
BRAF are mutated in several types of cancer, affecting the clinical response to EGFR …
BRAF are mutated in several types of cancer, affecting the clinical response to EGFR …
[HTML][HTML] Effect of BRAFmutational status on expression profiles in conventional papillary thyroid carcinomas
Abstract Background Whereas 40% to 70% of papillary thyroid carcinomas (PTCs) are
characterized by a BRAF mutation (BRAF mut), unified biomarkers for the genetically …
characterized by a BRAF mutation (BRAF mut), unified biomarkers for the genetically …
Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation
L Xu, R Ding, S Song, J Liu, J Li… - The Journal of Gene …, 2024 - Wiley Online Library
Background Aberrant activation of the phosphatidlinositol 3‐kinase (PI3K)/protein kinase B
(AKT)/mammalian target of rapamycin (mTOR) signaling pathway has been shown to play …
(AKT)/mammalian target of rapamycin (mTOR) signaling pathway has been shown to play …